chr2-240877556-G-A

Variant summary

Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong

The NM_000030.3(AGXT):​c.866G>A​(p.Arg289His) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000503 in 1,549,970 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.0013 ( 0 hom., cov: 33)
Exomes 𝑓: 0.00042 ( 1 hom. )

Consequence

AGXT
NM_000030.3 missense

Scores

7
12

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:1U:4B:1

Conservation

PhyloP100: -0.494
Variant links:
Genes affected
AGXT (HGNC:341): (alanine--glyoxylate aminotransferase) This gene is expressed only in the liver and the encoded protein is localized mostly in the peroxisomes, where it is involved in glyoxylate detoxification. Mutations in this gene, some of which alter subcellular targetting, have been associated with type I primary hyperoxaluria. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_benign. Variant got -2 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.009120911).

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
AGXTNM_000030.3 linkuse as main transcriptc.866G>A p.Arg289His missense_variant 9/11 ENST00000307503.4 NP_000021.1

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
AGXTENST00000307503.4 linkuse as main transcriptc.866G>A p.Arg289His missense_variant 9/111 NM_000030.3 ENSP00000302620 P1
AGXTENST00000470255.1 linkuse as main transcriptn.644G>A non_coding_transcript_exon_variant 1/32

Frequencies

GnomAD3 genomes
AF:
0.00130
AC:
198
AN:
152224
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00304
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00183
Gnomad ASJ
AF:
0.00634
Gnomad EAS
AF:
0.000193
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000220
Gnomad OTH
AF:
0.00287
GnomAD3 exomes
AF:
0.000980
AC:
150
AN:
153122
Hom.:
0
AF XY:
0.000952
AC XY:
77
AN XY:
80906
show subpopulations
Gnomad AFR exome
AF:
0.00360
Gnomad AMR exome
AF:
0.00138
Gnomad ASJ exome
AF:
0.00618
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.0000441
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000394
Gnomad OTH exome
AF:
0.00231
GnomAD4 exome
AF:
0.000416
AC:
582
AN:
1397628
Hom.:
1
Cov.:
31
AF XY:
0.000406
AC XY:
280
AN XY:
689272
show subpopulations
Gnomad4 AFR exome
AF:
0.00348
Gnomad4 AMR exome
AF:
0.00143
Gnomad4 ASJ exome
AF:
0.00601
Gnomad4 EAS exome
AF:
0.000140
Gnomad4 SAS exome
AF:
0.0000126
Gnomad4 FIN exome
AF:
0.0000206
Gnomad4 NFE exome
AF:
0.000181
Gnomad4 OTH exome
AF:
0.000966
GnomAD4 genome
AF:
0.00130
AC:
198
AN:
152342
Hom.:
0
Cov.:
33
AF XY:
0.00125
AC XY:
93
AN XY:
74492
show subpopulations
Gnomad4 AFR
AF:
0.00303
Gnomad4 AMR
AF:
0.00183
Gnomad4 ASJ
AF:
0.00634
Gnomad4 EAS
AF:
0.000193
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000221
Gnomad4 OTH
AF:
0.00284
Alfa
AF:
0.000733
Hom.:
0
Bravo
AF:
0.00175
TwinsUK
AF:
0.000270
AC:
1
ALSPAC
AF:
0.00
AC:
0
ESP6500AA
AF:
0.00173
AC:
7
ESP6500EA
AF:
0.000256
AC:
2
ExAC
AF:
0.000409
AC:
27
Asia WGS
AF:
0.000866
AC:
3
AN:
3478

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Uncertain:4Benign:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Primary hyperoxaluria, type I Pathogenic:1Uncertain:2
Pathogenic, no assertion criteria providedresearchClinical Biochemistry Laboratory, Health Services LaboratoryNov 27, 2014- -
Uncertain significance, criteria provided, single submitterclinical testingIllumina Laboratory Services, IlluminaApr 27, 2017This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. -
Uncertain significance, criteria provided, single submitterclinical testingCounsylDec 19, 2017- -
not provided Uncertain:1Benign:1
Likely benign, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 30, 2024- -
Uncertain significance, criteria provided, single submitterclinical testingEurofins Ntd Llc (ga)Mar 30, 2015- -
not specified Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpMay 26, 2022Variant summary: AGXT c.866G>A (p.Arg289His) results in a non-conservative amino acid change located in the Aminotransferase class V domain (IPR000192) of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00098 in 153122 control chromosomes, particularly at a frequency of 0.0036 within the African or African-American subpopulation in the gnomAD database. The observed variant frequency within African or African-American control individuals in the gnomAD database is approximately 1.5-fold of the estimated maximal expected allele frequency for a pathogenic variant in AGXT causing Primary Hyperoxaluria Type 1 phenotype (0.0024), suggesting that the variant may be a benign polymorphism. Nevertheless, c.866G>A has been reported in the literature in a homozygous individual affected with Primary Hyperoxaluria Type 1 (Murad_2021). It has also been reported as part of complex alleles in additional individuals affected with Primary Hyperoxaluria Type 1 (Williams_2009, Williams_2015). These reports do not provide unequivocal conclusions about association of the variant with Primary Hyperoxaluria Type 1. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. One ClinVar submitter (evaluation after 2014) cites the variant as likely benign and three ClinVar submitters (evaluation after 2014) cite it as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.083
BayesDel_addAF
Benign
-0.18
T
BayesDel_noAF
Uncertain
-0.040
CADD
Benign
13
DANN
Uncertain
0.99
DEOGEN2
Uncertain
0.54
D
Eigen
Benign
-0.72
Eigen_PC
Benign
-0.75
FATHMM_MKL
Benign
0.038
N
LIST_S2
Benign
0.81
T
M_CAP
Uncertain
0.12
D
MetaRNN
Benign
0.0091
T
MetaSVM
Uncertain
-0.095
T
MutationAssessor
Uncertain
2.2
M
MutationTaster
Benign
0.82
N
PrimateAI
Benign
0.30
T
PROVEAN
Benign
-2.3
N
REVEL
Uncertain
0.56
Sift
Benign
0.076
T
Sift4G
Benign
0.12
T
Polyphen
0.0040
B
Vest4
0.095
MVP
0.86
MPC
0.037
ClinPred
0.0078
T
GERP RS
-0.55
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.1
Varity_R
0.14
gMVP
0.76

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs61729604; hg19: chr2-241816973; COSMIC: COSV56756069; COSMIC: COSV56756069; API